Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2003, p. 418-420, Vol. 47, No. 1
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.1.418-420.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus
Patrick Grohs,1 Marie-Dominique Kitzis,2 and Laurent Gutmann1,3*
Hôpital Européen Georges Pompidou,1
Hôpital Saint Joseph,2
Laboratoire de Recherche Moléculaire sur les Antibiotiques, Université Paris VI, Paris, France3
Received 19 April 2002/
Returned for modification 24 July 2002/
Accepted 23 October 2002
The in vitro activities of linezolid were determined alone and in combination with vancomycin, ciprofloxacin, gentamicin, fusidic acid, or rifampin against five methicillin-susceptible Staphylococcus aureus (MSSA) and five methicillin-resistant S. aureus (MRSA) strains. Similar responses were obtained against MSSA and MRSA. When combined with fusidic acid, gentamicin, or rifampin, linezolid prevented selection of resistant mutants but showed no synergy. When linezolid was combined with vancomycin and ciprofloxacin, a slight antagonism was observed. While the combination with linezolid may reduce the emergence of mutants resistant to the associated drugs, the absence of synergy, especially in the case of vancomycin and ciprofloxacin, does not argue in favor of such combinations.
* Corresponding author. Mailing address: Laboratoire de Microbiologie, Hôpital Européen Georges Pompidou, 20, rue Leblanc, 75908 Paris Cedex 15, France. Phone: 33 1 56 09 39 51. Fax: 33 1 56 09 24 46. E-mail:
laurent.gutmann{at}hop.egp.ap-hop-paris.fr.
Antimicrobial Agents and Chemotherapy, January 2003, p. 418-420, Vol. 47, No. 1
0066-4804/03/$08.00+0 DOI: 10.1128/AAC.47.1.418-420.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Nguyen, H. M., Graber, C. J.
(2009). Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother
0: dkp377v1-dkp377
[Abstract]
[Full Text]
-
Baldoni, D., Haschke, M., Rajacic, Z., Zimmerli, W., Trampuz, A.
(2009). Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection. Antimicrob. Agents Chemother.
53: 1142-1148
[Abstract]
[Full Text]
-
Perlroth, J., Kuo, M., Tan, J., Bayer, A. S., Miller, L. G.
(2008). Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature. Arch Intern Med
168: 805-819
[Abstract]
[Full Text]
-
Jones, R. N., Ross, J. E., Fritsche, T. R., Sader, H. S.
(2006). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother
57: 279-287
[Abstract]
[Full Text]
-
Scheetz, M., Reddy, P., Postelnick, M., Flaherty, J.
(2005). In vivo synergy of daptomycin plus a penicillin agent for MRSA?. J Antimicrob Chemother
55: 398-399
[Full Text]
-
Krueger, W. A., Kottler, B., Will, B. E., Heininger, A., Guggenberger, H., Unertl, K. E.
(2004). Treatment of Meningitis Due to Methicillin-Resistant Staphylococcus epidermidis with Linezolid. J. Clin. Microbiol.
42: 929-932
[Abstract]
[Full Text]
-
Wagenlehner, F. M. E., Wydra, S., Onda, H., Kinzig-Schippers, M., Sorgel, F., Naber, K. G.
(2003). Concentrations in Plasma, Urinary Excretion, and Bactericidal Activity of Linezolid (600 Milligrams) versus Those of Ciprofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose. Antimicrob. Agents Chemother.
47: 3789-3794
[Abstract]
[Full Text]